MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务。

Asciminib hydrochloride

CAS No. : 2119669-71-3

MCE 站：Asciminib hydrochloride

产品活性：Asciminib (ABL001) hydrochloride 是一种有效和选择性的变构 BCR-ABL1 抑制剂，抑制 Ba/F3 细胞生长的 IC₅₀ 值为 0.25 nM。

研究领域：Protein Tyrosine Kinase/RTK

作用靶点：Bcr-Abl

In Vitro: Asciminib (ABL001) hydrochloride binds to the myristoyl pocket of ABL1 ａnd induces the formation of an inactive kinase conformation.
Asciminib hydrochloride binds potently (dissociation constant=0.5-0.8 nM) ａnd selectively to the myristoyl pocket of ABL1 ａnd induces the inactive C-terminal helix conformation. Asciminib hydrochloride exhibits the same non-ATP-competitive biochemical kinetics as the BCRABL inhibitor GNF-2 but with approximately 100-fold greater potency.
Asciminib hydrochloride lacks activity against more than 60 kinases, including SRC, ａnd is similarly inactive against G-protein-coupled receptors, ion channels, nuclear receptors ａnd transporters.
In BCRABL1-transformed Ba/F3 cells grown without IL-3, Asciminib hydrochloride has an anti-proliferative with IC₅₀ value of 0.25 nM. In the CML blast-phase cell line KCL-22, Asciminib hydrochloride inhibits phosphorylation of both STAT5 (Tyr694; pSTAT5) ａnd BCRABL1 (Tyr245; pBCRABL1) after 1 h using concentrations that correlate with those required for inhibition of cell proliferation.
Asciminib hydrochloride is selectively active against all BCRABL1 lines (IC₅₀ value of 120 nM), irrespective of the presence of either the p210 or the p190 BCRABL1 isoform.

In Vivo: Single doses of 7.5, 15 ａnd 30 mg/kg Asciminib, administered to mice bearing KCL- 22 xenografts, inhibits pSTAT5 (Tyr694), which return to baseline at 10, 12 ａnd 16-20 h after administration of the dose, respectively. In mice implanted with KCL-22 tumors, the minimum dose of Asciminib required for complete regression is 7.5 mg/kg twice a day (BID) or 30 mg/kg once a day (QD), ａnd is tolerated at doses up to 250 mg/kg BID.

相关产品：Drug Repurposing Compound Library Plus  |  FDA-Approved Drug Library Plus  |  FDA-Approved Drug Library Mini  |  Bioactive Compound Library Plus  |  Kinase Inhibitor Library  |  Protein Tyrosine Kinase Compound Library  |  FDA-Approved Drug Library  |  Anti-Cancer Compound Library  |  Drug Repurposing Compound Library  |  Cytoskeleton Compound Library  |  FDA Approved & Pharmacopeial Drug Library  |  Anti-Alzheimer＇s Disease Compound Library  |  Anti-Blood Cancer Compound Library  |  Anti-Parkinson＇s Disease Compound Library  |  Neurodegenerative Disease-related Compound Library  |  Rare Diseases Drug Library  |  FDA-Approved Anticancer Drug Library  |  Dasatinib  |  Nocodazole  |  Imatinib  |  Ponatinib  |  Nilotinib  |  Bosutinib  |  Degrasyn  |  Asciminib  |  Rebastinib  |  AT9283  |  KW-2449  |  Olverembatinib  |  LXH254  |  Bafetinib  |  DPH  |  Flumatinib  |  PD173955  |  GNF-7  |  XL228  |  AST 487  |  Vodobatinib  |  Cenisertib  |  CZC-8004  |  GNF-2  |  SIAIS178

热门产品线：重组蛋白  |  化合物库  |  天然产物  |  染料试剂  |  PROTAC  |  同位素标记物  |  寡核苷酸

Trending products：Recombinant Proteins  |  Bioactive Screening Libraries  |  Natural Products  |  Dye Reagents  |  PROTAC  |  Isotope-Labeled Compounds  |  Oligonucleotides

品牌介绍:
•   MCE (MedChemExpress) 拥有数百种全球独家化合物，我们致力于为全球科研客户提供*新*全的高品质小分子活性化合物；
•   10,000 多种高选择性抑制剂、激动剂涉及各热门信号通路及疾病领域；
•   设有专业的实验中心和严格的质控、验证体系；
•   提供 LC/MS、NMR、HPLC、手性分析、元素分析等各项质检报告，确保产品的高纯度、高品质；
•   产品的生物活性多经各国客户实验验证；
•   Nature, Cell, Science 等多种期刊及制药收录了MCE客户的科研成果；
•   专业团队跟踪*新的制药及生命科学研究进展，为您提供全球*新的活性化合物；
•   与世界各大制药公司及知名科研机构建立了长期的合作。